Extracorporal Immunopharmacotherapy.

The methods of extracorporal immunopharmacotherapy may be attributed to cell engineering immunocorrection therapy and allows to apply regulatory immune cells and their short-distance mediators after pharmaceutical activation in vitro (extracorporally). The therapy implores: (1) in vitro drug-dependent activation of leukocytes obtained from patient's blood, and (2) withdrawal of the activatory drugs and reinfusion of activated leukocytes back to the patient. By doing this it is possible to perform drug treatment of the patient not in his body, but in vitro through stimulating only a part of his cells. This significantly abolishes endotoxication and prevents the endless part of immune cells from drug-dependent cytotoxicity. The methods of extracorporal immunopharmacotherapy gives reliable opportunities for managing altered parameters of the immune system towards norm in fast and fair efficient manner. Here we report some positive results of application of extracorporal immunopharmacotherapy in patients with atopic asthma, Layell and severe atopic syndromes.